Founded in 2015
ThioLogics is a UCL spinout company developing a technology platform that will enable the homogeneous modification of native polypeptides. Specifically, they have discovered groundbreaking technology, based on Next Generation Maleimides, that allows the selective bridging and functionalisation of disulfide bonds in antibodies, proteins and peptides. The company is particularly focused on the application of their technology to the assembly of homogeneous antibody conjugates.
Technology that will allow modification of antibodies to yield homogeneous products is highly desirable. In particular, it has been demonstrated that homogeneous antibody drug conjugates (ADCs) have a greatly improved therapeutic index over analogous heterogeneous formulations. Introducing greater homogeneity into antibody conjugates will also greatly simplify process and development issues, thereby reducing costs.